Boutonnat J - Search Results

1

Synchrotron microbeam radiation therapy for rat brain tumor palliation-influence of the microbeam width at constant valley dose.

Serduc R, Bouchet A, Bräuer-Krisch E, Laissue JA, Spiga J, Sarun S, Bravin A, Fonta C, Renaud L, Boutonnat J, Siegbahn EA, Estève F, Le Duc G. Serduc R, et al. Among authors: boutonnat j. Phys Med Biol. 2009 Nov 7;54(21):6711-24. doi: 10.1088/0031-9155/54/21/017. Epub 2009 Oct 20. Phys Med Biol. 2009. PMID: 19841517

2

Chalcone JAI-51 improves efficacy of synchrotron microbeam radiation therapy of brain tumors.

Bouchet A, Boumendjel A, Khalil E, Serduc R, Bräuer E, Siegbahn EA, Laissue JA, Boutonnat J. Bouchet A, et al. Among authors: boutonnat j. J Synchrotron Radiat. 2012 Jul;19(Pt 4):478-82. doi: 10.1107/S0909049512015105. Epub 2012 May 4. J Synchrotron Radiat. 2012. PMID: 22713877 Free article.

3

Chalcones derivatives acting as cell cycle blockers: potential anti cancer drugs?

Boumendjel A, Ronot X, Boutonnat J. Boumendjel A, et al. Among authors: boutonnat j. Curr Drug Targets. 2009 Apr;10(4):363-71. doi: 10.2174/138945009787846416. Curr Drug Targets. 2009. PMID: 19355861 Review.

4

A novel chalcone derivative which acts as a microtubule depolymerising agent and an inhibitor of P-gp and BCRP in in-vitro and in-vivo glioblastoma models.

Boumendjel A, McLeer-Florin A, Champelovier P, Allegro D, Muhammad D, Souard F, Derouazi M, Peyrot V, Toussaint B, Boutonnat J. Boumendjel A, et al. Among authors: boutonnat j. BMC Cancer. 2009 Jul 20;9:242. doi: 10.1186/1471-2407-9-242. BMC Cancer. 2009. PMID: 19619277 Free PMC article.

5

Cytotoxicity of chalcone derivatives towards glioblastoma.

Champelovier P, Mininno M, Duchamp E, Nicolle E, Curri V, Boumendjel A, Boutonnat J. Champelovier P, et al. Among authors: boutonnat j. Anticancer Res. 2011 Oct;31(10):3213-8. Anticancer Res. 2011. PMID: 21965728

6

Cellular and molecular mechanisms activating the cell death processes by chalcones: Critical structural effects.

Champelovier P, Chauchet X, Hazane-Puch F, Vergnaud S, Garrel C, Laporte F, Boutonnat J, Boumendjel A. Champelovier P, et al. Among authors: boutonnat j. Toxicol In Vitro. 2013 Dec;27(8):2305-15. doi: 10.1016/j.tiv.2013.09.021. Epub 2013 Oct 14. Toxicol In Vitro. 2013. PMID: 24134853

7

Modulation of P-glycoprotein-mediated multidrug resistance by flavonoid derivatives and analogues.

Hadjeri M, Barbier M, Ronot X, Mariotte AM, Boumendjel A, Boutonnat J. Hadjeri M, et al. Among authors: boutonnat j. J Med Chem. 2003 May 22;46(11):2125-31. doi: 10.1021/jm021099i. J Med Chem. 2003. PMID: 12747785

8

Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).

Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, Boutonnat J. Boumendjel A, et al. Among authors: boutonnat j. J Med Chem. 2005 Nov 17;48(23):7275-81. doi: 10.1021/jm050705h. J Med Chem. 2005. PMID: 16279786

9

Flavonoids as RTK inhibitors and potential anticancer agents.

Teillet F, Boumendjel A, Boutonnat J, Ronot X. Teillet F, et al. Among authors: boutonnat j. Med Res Rev. 2008 Sep;28(5):715-45. doi: 10.1002/med.20122. Med Res Rev. 2008. PMID: 18080331 Review.

10

2-Arylidenedihydroindole-3-ones: design, synthesis, and biological activity on bladder carcinoma cell lines.

Gerby B, Boumendjel A, Blanc M, Bringuier PP, Champelovier P, Fortuné A, Ronot X, Boutonnat J. Gerby B, et al. Among authors: boutonnat j. Bioorg Med Chem Lett. 2007 Jan 1;17(1):208-13. doi: 10.1016/j.bmcl.2006.09.057. Epub 2006 Oct 16. Bioorg Med Chem Lett. 2007. PMID: 17049235

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

79 results

Search Page

Filters